113 related articles for article (PubMed ID: 10673757)
1. 3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Creutzig U; Körholz D; Niemeyer CM; Kabisch K; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Leukemia; 2000 Feb; 14(2):340-2. PubMed ID: 10673757
[No Abstract] [Full Text] [Related]
2. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
Creutzig U; Körholz D; Niemeyer CM; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Klin Padiatr; 2000; 212(4):163-8. PubMed ID: 10994544
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Lee MH; Kim SY
Leuk Lymphoma; 2016 Oct; 57(10):2268-74. PubMed ID: 26750985
[TBL] [Abstract][Full Text] [Related]
4. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
7. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
8. [Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].
Erttmann R; Bode U; Erb N; Forcadell de Dios P; Gutjahr P; Haas R; Kuhn N; Siewert H; Landbeck G
Klin Padiatr; 1988; 200(3):200-4. PubMed ID: 3062256
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Anderlini P; Benjamin RS; Wong FC; Kantarjian HM; Andreeff M; Kornblau SM; O'Brien S; Mackay B; Ewer MS; Pierce SA
J Clin Oncol; 1995 Nov; 13(11):2827-34. PubMed ID: 7595745
[TBL] [Abstract][Full Text] [Related]
11. Escalated anthracycline dose in adult AML.
Balakrishnan VS
Lancet Oncol; 2017 May; 18(5):e253. PubMed ID: 28416149
[No Abstract] [Full Text] [Related]
12. Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin.
Peña M; Serra J; Ribera JM
Med Clin (Barc); 2018 Dec; 151(12):506-507. PubMed ID: 29731139
[No Abstract] [Full Text] [Related]
13. The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Kobayashi T; Ichikawa M; Nannya Y; Kurokawa M
Jpn J Clin Oncol; 2013 Oct; 43(10):1047-51. PubMed ID: 23956441
[TBL] [Abstract][Full Text] [Related]
14. First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.
Ahmed Z; Davaro E; Batanian J; Verma N
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31101747
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
16. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
17. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.
Abrahamsson J; Forestier E; Heldrup J; Jahnukainen K; Jónsson OG; Lausen B; Palle J; Zeller B; Hasle H
J Clin Oncol; 2011 Jan; 29(3):310-5. PubMed ID: 21149663
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin including regimens in acute myelogenous leukemia in elderly patients.
Leone G; Sica S; Pagano L
Crit Rev Oncol Hematol; 1999 Sep; 32(1):59-68. PubMed ID: 10586356
[No Abstract] [Full Text] [Related]
19. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
20. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
